Tumor-specific, Schedule-dependent Interaction between Tirapazamine (SR 4233) and Cisplatin

Cancer Research

Volumn 53, Issue 19, 1993, Pages 4633-4636

  Done, Mary Jo ^a   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NITROGEN; TIRAPAZAMINE; UREA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY INJURY; LD 50; LEUKOCYTE COUNT; LEUKOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR;

ANIMAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FIBROSARCOMA; KIDNEY; LEUKOCYTE COUNT; LEUKOPENIA; MICE; MICE, INBRED C3H; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 84965808588     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brown, J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer, 67: 1163-1170, 1993.
2. Moulder, J.E., and Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev., 5: 313-341, 1987.
3. Hockel, M., Schlenger, K., Knoop, C., and Vaupel, P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized 02 tension measurements. Cancer Res., 51: 6098-6102, 1991.
4. Mueller-Klieser, W., Vaupel, R., Manz, R., and Schmidseder, R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. Oncol. Biol. Phys., 7: 1397-1404, 1981.
5. Vaupel, R., Schlenger, K., Knoop, C., and Hockel, M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized 02 tension measurements. Cancer Res., 51: 3316-3322, 1991.
6. Bush, R.S., Jenkin, R.D.T., Allt, W.E.C., Beale, F.A., Bean, H., Denbo, A.J., and Pringle, J.F. Definite evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer, 37 (Suppl. 3): 302-306, 1978.
7. Gatenby, R.A., Kessler, H.B., Rosenblum, J.S., Coia, L.R., Moldofsky, P.J., Hartz, W.H., and Broder, G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14: 831-838, 1988.
8. Hockel, M., Knoop, C., Schlenger, K., Vorndran, B., Baubmann, E., Mitze, M., Knapstein, P.G., and Vaupel, P. Intratumoral p. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 26: 45-50, 1993.
9. Brown, J.M., and Lemmon, M.J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50: 7745-7749, 1990.
10. Brown, J.M., and Lemmon, M.J. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol., 20: 151-156, 1991.
11. Brown, J.M., and Lemmon, M.J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20: 457-461, 1991.
12. Kennedy, K.A. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des., 2: 181-94, 1987.
13. Sartorelli, A.C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48: 775-778, 1988.
14. Tannock, I., and Guttman, P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br. J. Cancer, 42: 245-248, 1981.
15. Grau, C., and Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol., 13: 301-309, 1988.
16. Tannock, I.F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and Adriamycin. Br. J. Cancer, 42: 861-870, 1980.
17. Siemann, D.W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 10: 1585-1594, 1984.
18. Taylor, Y.C., Evans, J.W., and Brown, J.M. Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res., 43: 3175-3181, 1983.
19. Murray, D., and Meyn, R.E. Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. Br. J. Cancer, 47: 195-203, 1983.
20. Holden, S.A., Teicher, B.A., Ara, G., Herman, T.S., and Coleman, C.N. Enhancement of alkylating agent activity by SR-4233 in the FSallC murine fibrosarcoma. J. Natl. Cancer Inst., 84: 187-193, 1992.
21. Zeman, E.M., Hirst, V.K., Lemmon, M.J., and Brown, J.M. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother. Oncol., 12: 209-218, 1988.
22. Dorie, M.J., and Kallman, R.F. Reoxygenation in the RIF-1 tumor after chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 24: 295-299, 1992.
23. Twentyman, P.R., Brown, J.M., Gray, J.W., Franko, A.J., Scoles, M.A., and Kallman, R.F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J. Natl. Cancer Inst., 64: 595-604, 1980.
24. Shurig, J.E., Bradner, W.T., Huftalen, J.B., Doyle, G.J., and Gylys, J.A. Toxic side effects of platinum analogs. In: A.W. Prestayko, S. T Crooke, and S.K. Carter (eds.), Cisplatin Current Status and New Developments, pp. 227-236. New York: Academic Press, 1980.
25. Teicher, B.A., Lazo, J.S., and Sartorelli, A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41: 73-81, 1981.
26. Durand, R.E. Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulation of a tumor model. Int. J. Cancer, 44: 911-917, 1989.
27. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2: 275-280, 1990.
28. Chen, G., Frei, E., and Zeller, W.J. Determination of intracellular reduced glutathione and glutathione enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines. Cancer Lett., 46: 207-211, 1989.
29. Andrews, P.A., Schiefer, M.A., Murphy, M., and Howell, S.B. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem.-Biol. Interact., 65: 51-58, 1988.